Next Article in Journal
CDK Regulation of Meiosis: Lessons from S. cerevisiae and S. pombe
Previous Article in Journal
The Potential Effect of Aberrant Testosterone Levels on Common Diseases: A Mendelian Randomization Study
Previous Article in Special Issue
Comparative Analysis of the Minimum Number of Replication Origins in Trypanosomatids and Yeasts
Open AccessReview

Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery

1
Department of Microbiology, Adamas University, Kolkata, West Bengal 700 126, India
2
Department of Pathology and Microbiology, Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC J2S 2M2, Canada
3
Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte MG 30190-009, Brazil
*
Author to whom correspondence should be addressed.
Genes 2020, 11(7), 722; https://doi.org/10.3390/genes11070722
Received: 4 June 2020 / Revised: 23 June 2020 / Accepted: 26 June 2020 / Published: 29 June 2020
(This article belongs to the Special Issue Kinetoplastid Genomics and Beyond)
Leishmaniasis (Leishmania species), sleeping sickness (Trypanosoma brucei), and Chagas disease (Trypanosoma cruzi) are devastating and globally spread diseases caused by trypanosomatid parasites. At present, drugs for treating trypanosomatid diseases are far from ideal due to host toxicity, elevated cost, limited access, and increasing rates of drug resistance. Technological advances in parasitology, chemistry, and genomics have unlocked new possibilities for novel drug concepts and compound screening technologies that were previously inaccessible. In this perspective, we discuss current models used in drug-discovery cascades targeting trypanosomatids (from in vitro to in vivo approaches), their use and limitations in a biological context, as well as different examples of recently discovered lead compounds. View Full-Text
Keywords: trypanosomatids; neglected tropical diseases; Leishmania; Trypanosoma cruzi; Trypanosoma brucei; drug discovery; in vitro models; in vivo models; genomics; drug resistance trypanosomatids; neglected tropical diseases; Leishmania; Trypanosoma cruzi; Trypanosoma brucei; drug discovery; in vitro models; in vivo models; genomics; drug resistance
Show Figures

Graphical abstract

MDPI and ACS Style

Bhattacharya, A.; Corbeil, A.; do Monte-Neto, R.L.; Fernandez-Prada, C. Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery. Genes 2020, 11, 722.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop